Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib (RINVOQ) in Korean Adult Patients With Ulcerative Colitis or Crohn's Disease

NCT06459297 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06459297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06459297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib (RINVOQ) in Korean Adult Patients With Ulcerative Colitis or Crohn's Disease
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
June 24, 2024
Completion date
December 9, 2025
Enrollment
105 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ulcerative colitis